Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on August 30, 2021 to

Original languageEnglish
Pages (from-to)2130
Number of pages1
JournalInternational Journal of Clinical Oncology
Volume26
Issue number11
DOIs
Publication statusPublished - 2021 Nov
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)'. Together they form a unique fingerprint.

Cite this